A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

Inclusion Criteria: * Chronic Myeloid Leukemia in the Chronic Phase * 20 years old over * ECOG performance status (PS) score 0-2 * Patients for major molecular response (MMR) with no CMR * Adequate organ function (hepatic, renal and lung) * Signed written informed consent Exclusion Criteria: * A case with the double cancer of the activity * Women who are pregnant or breastfeeding * The case of Pleural effusion clearly * Patients with complications or a history of severe or uncontrolled cardiovascular failure following * have a Myocardial infarction within 6 months * have an Angina within 3 months * have a Congestive heart failure within 3 months * have a suspected congenital QT syndrome * have a QTc interval of more than 450msec at baseline * A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy * Prior treatment with dasatinib * Subjects with T315I, F317L and V299L BCR-ABL point mutations